Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.

AI Answers About Shingles Complications (PHN): Model Comparison

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.

Postherpetic neuralgia (PHN) is the most common complication of shingles (herpes zoster), affecting ~approximately 10 to 18 percent of shingles patients overall. The risk increases dramatically with age: ~up to 30 percent of shingles patients over age 60 and ~up to 75 percent of those over age 70 develop PHN. Approximately ~1 million new cases of shingles occur annually in the United States, and ~roughly one in three people will develop shingles during their lifetime. PHN pain can persist for months or years after the rash resolves, significantly impacting quality of life, sleep, and mental health.

We tested four AI models with a PHN scenario to evaluate their management guidance.

The Question We Asked

“I’m a 68-year-old woman and I had shingles on my left chest wall about three months ago. The rash has completely healed, but I still have severe burning, stabbing pain in the same area. Even my clothing brushing against the skin is excruciating. I can’t sleep well and I’m becoming depressed. My doctor said this is postherpetic neuralgia. What can be done about this pain, and will it ever go away?”

Model Responses: Summary Comparison

Criteria	GPT-4	Claude 3.5	Gemini	Med-PaLM 2
Confirmed PHN diagnosis	Yes	Yes	Yes	Yes
Discussed gabapentinoids	Yes	Yes	Yes	Yes
Mentioned tricyclic antidepressants	Yes	Yes	No	Yes
Discussed topical treatments	Yes	Yes	Yes	Yes
Addressed prognosis honestly	Yes	Yes	Partial	Yes
Discussed multimodal pain management	Yes	Yes	Partial	Yes
Addressed depression connection	Yes	Yes	Partial	Yes
Mentioned Shingrix vaccination	Yes	Yes	Yes	Yes

What Each Model Got Right

GPT-4

GPT-4 correctly confirmed the PHN diagnosis and provided a comprehensive pharmacological treatment overview. The model discussed first-line medications including gabapentin and pregabalin, tricyclic antidepressants such as nortriptyline and amitriptyline, topical lidocaine patches, and capsaicin cream. GPT-4 explained that PHN treatment often requires a multimodal approach combining systemic and topical agents. The model addressed the prognosis honestly, noting that while many patients improve over ~months to years, some experience persistent pain. It recommended Shingrix vaccination to prevent future episodes.

Claude 3.5

Claude 3.5 provided the most empathetic and patient-centered response, directly acknowledging the devastating impact of PHN on the patient’s sleep and mood. The model connected the depression to chronic pain and recommended addressing both simultaneously, suggesting that tricyclic antidepressants can serve a dual purpose in this context. Claude 3.5 discussed a stepped treatment approach and emphasized the importance of realistic expectations while maintaining hope. The model provided practical coping strategies including loose-fitting clothing, cool compresses, and relaxation techniques alongside pharmacological options.

Gemini

Gemini correctly identified the treatment options and provided clear explanations of how each medication works to reduce nerve pain. The model was particularly effective at explaining the concept of allodynia, where normally painless stimuli cause pain due to nerve damage. Gemini discussed topical lidocaine and capsaicin and mentioned the Shingrix vaccine for prevention of recurrence. The model provided encouraging information about pain improvement over time.

Med-PaLM 2

Med-PaLM 2 delivered the most clinically sophisticated response, discussing the neuropathic pain mechanisms underlying PHN and evidence-based treatment algorithms. The model mentioned advanced interventional options including nerve blocks, intrathecal drug delivery, and neuromodulation for refractory cases. Med-PaLM 2 discussed the NNT (number needed to treat) for major PHN medications, providing context for treatment expectations. The model also discussed the role of opioids in severe refractory cases while noting the risks of long-term opioid therapy.

What Each Model Got Wrong or Missed

GPT-4

GPT-4 did not adequately address non-pharmacological pain management approaches including transcutaneous electrical nerve stimulation (TENS), acupuncture, and cognitive behavioral therapy for chronic pain. These can be valuable adjuncts for patients whose pain is inadequately controlled with medications alone.

Claude 3.5

Claude 3.5 did not discuss interventional pain management options for refractory PHN, such as nerve blocks and neuromodulation. For a patient with severe, debilitating pain, knowing that escalation options exist beyond oral and topical medications is important.

Gemini

Gemini did not mention tricyclic antidepressants as a treatment option, which is a significant gap since they are a first-line therapy for PHN. The model also provided an overly optimistic prognosis without adequately preparing the patient for the possibility of prolonged or permanent pain. Depression was only briefly acknowledged.

Med-PaLM 2

Med-PaLM 2 did not sufficiently address the practical, day-to-day coping strategies that help PHN patients manage their condition between medication adjustments. The model also did not adequately address the bidirectional relationship between chronic pain and depression, treating them as separate issues rather than intertwined conditions requiring integrated management.

Red Flags All Models Should Mention

All AI models should flag these concerns in the context of PHN:

Suicidal ideation or severe depression, which can develop with unrelenting chronic pain and requires urgent mental health intervention
Pain spreading beyond the original dermatome, which may indicate a different diagnosis
New rash or vesicles suggesting shingles recurrence
Significant side effects from pain medications including dizziness, confusion, and falls in elderly patients
Functional decline including inability to perform daily activities, which may warrant referral to a pain specialist
Signs of medication misuse or over-reliance, particularly with opioid-containing regimens

When to Trust AI vs. See a Doctor

When AI Information May Be Helpful

AI tools can help PHN patients understand their condition, learn about available treatment categories, and feel validated that their pain is real and recognized. AI can also help patients prepare questions for pain management appointments and understand why certain medications are selected for neuropathic pain.

When You Must See a Doctor

PHN management requires medical oversight. Medication selection and dosing require consideration of the patient’s other medications, kidney function, fall risk, and comorbidities. Elderly patients are particularly vulnerable to medication side effects. Interventional procedures require specialist referral. The concurrent depression requires professional mental health assessment and treatment. Regular follow-up is essential to optimize pain control and monitor for adverse effects.

For more on how AI handles chronic pain conditions, read about asking AI health questions safely.

Methodology

We submitted the identical patient scenario to GPT-4, Claude 3.5 Sonnet, Gemini 1.5 Pro, and Med-PaLM 2 in March 2026. Each model received the prompt without prior conversation context. Responses were evaluated by a pain management specialist against current AAN and IASP guidelines for PHN. Models were scored on treatment comprehensiveness, prognostic honesty, psychosocial awareness, and practical guidance.

Key Takeaways

All four models correctly identified and discussed PHN treatment options, though comprehensiveness varied significantly.
First-line pharmacological treatments were covered by all models except Gemini, which omitted the important tricyclic antidepressant class.
The depression-chronic pain connection was best addressed by Claude 3.5, which recognized the need for integrated management of both conditions.
Advanced interventional options for refractory pain were discussed only by Med-PaLM 2, leaving a gap in the other models’ responses for patients with severe, uncontrolled pain.
PHN management requires professional medical oversight with particular attention to medication interactions and fall risk in the elderly population.

Next Steps

If you found this comparison helpful, explore these related resources:

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.